Erasca (ERAS) Other Non-Current Liabilities (2020 - 2026)
Erasca (ERAS) reported Other Non-Current Liabilities of $340000.0 for Q1 2026, up 35.46% on a YoY basis from $251000.0 in Q1 2025, and down 14.79% quarter-over-quarter from $399000.0 in Q4 2025.
Erasca (ERAS) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Erasca has reported Other Non-Current Liabilities for 7 years, with the latest figure at $340000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 35.46% year-over-year to $340000.0; the trailing twelve-month figure through Mar 2026 stood at $340000.0 (up 35.46% YoY), and the FY2025 full-year result was $399000.0, up 10.22% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $340000.0, down from $399000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $761000.0 in Q3 2023, with the low at $82000.0 in Q2 2024.
- Historically, Other Non-Current Liabilities has averaged $444142.9 across 5 years, with a median of $397000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 262.66% — and 2024, when it tumbled 88.24%.
- Erasca's Other Non-Current Liabilities stood at $573000.0 in 2022, then decreased by 1.22% to $566000.0 in 2023, then tumbled by 36.04% to $362000.0 in 2024, then gained by 10.22% to $399000.0 in 2025, then dropped by 14.79% to $340000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $340000.0 (Q1 2026), $399000.0 (Q4 2025), and $395000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 251,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 340,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 559,000.00 |
| Dec 31, 2023 | 566,000.00 |
| Sep 30, 2023 | 761,000.00 |
| Jun 30, 2023 | 697,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Dec 31, 2021 | 158,000.00 |
| Dec 31, 2020 | 1.62 Mn |